BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Benefit in Phase 3 Trial
Bitget2026/10/26 09:05- BioNTech and DualityBio reported trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial.
- Progression-free survival improved significantly but modestly versus chemotherapy in chemotherapy-naive patients with HR-positive, HER2-low metastatic breast cancer progressing on endocrine therapy.
- Interim overall survival data were not yet mature.
- Interstitial lung disease occurred more frequently than in earlier studies; most cases were mild or moderate, but some were severe or fatal.
- The partners see limited potential benefit relative to available treatments and will review the data to decide next steps.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla (TSLA.US) Cybercab limited pre-orders open: priced at $29,990, with an additional monthly operating fee of $299
According to reports, Tesla has invited select customers to reserve the Cybercab, taking a step toward launching this self-driving model to general consumers.
Fed Vice Chair Sets the Tone: Inflation Is the "Most Important Signal," Interest Rate Decisions Depend on It
Federal Reserve Vice Chair Philip Jefferson stated that when policymakers consider whether to raise interest rates further, inflation has become the most important metric.
Elon Musk Leads Petition! Silicon Valley Supports Jensen Huang as Tens of Thousands Call for the Return of the Founder
Elon Musk has publicly co-signed a petition in support of Jensen Huang’s return to NVIDIA. The number of signatures on the petition website has surpassed 14,000, causing the site to almost crash due to a surge in traffic. What is raising further alarm in the capital markets is that NVIDIA’s core engineers have made collective statements, warning that if senior management mishandles the situation, key technical talent may leave, potentially undermining NVIDIA’s competitive moat.
NVIDIA (NVDA.US) downplays CEO succession rumors: no official contact with potential candidates yet, calling all speculation "premature"
Nvidia has downplayed speculation that the company is already in contact with potential CEO candidates, stating that it is still in the process of selecting a headhunting firm to seek a successor for ousted leader Jensen Huang.
Crypto prices
More
